Head to Head Analysis: Opiant Pharmaceuticals (OPNT) versus Amerigo Resources (ARREF)
Opiant Pharmaceuticals (NASDAQ:OPNT) and Amerigo Resources (OTCMKTS:ARREF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Insider & Institutional Ownership
4.8% of Opiant Pharmaceuticals shares are owned by institutional investors. 37.9% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Opiant Pharmaceuticals and Amerigo Resources’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$18.45 million||2.65||$6.58 million||$2.94||5.90|
|Amerigo Resources||$134.03 million||0.82||$7.98 million||$0.04||15.56|
Amerigo Resources has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Amerigo Resources, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Opiant Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Amerigo Resources has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.
This table compares Opiant Pharmaceuticals and Amerigo Resources’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Opiant Pharmaceuticals and Amerigo Resources, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opiant Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 84.44%. Given Opiant Pharmaceuticals’ higher possible upside, research analysts plainly believe Opiant Pharmaceuticals is more favorable than Amerigo Resources.
Amerigo Resources beats Opiant Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Amerigo Resources Company Profile
Amerigo Resources Ltd., through its subsidiary, produces and sells copper and molybdenum concentrates from Codelco's El Teniente underground mine in Chile. The company was formerly known as Golden Temple Mining Corp. and changed its name to Amerigo Resources Ltd. in March 2002. Amerigo Resources Ltd. was founded in 1984 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.